RT Journal Article
SR Electronic
T1 SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267417
DO 10.1101/2021.12.08.21267417
A1 Sandile Cele
A1 Laurelle Jackson
A1 Khadija Khan
A1 David S. Khoury
A1 Thandeka Moyo-Gwete
A1 Houriiyah Tegally
A1 Cathrine Scheepers
A1 Daniel Amoako
A1 Farina Karim
A1 Mallory Bernstein
A1 Gila Lustig
A1 Derseree Archary
A1 Muneerah Smith
A1 Yashica Ganga
A1 Zesuliwe Jule
A1 Kajal Reedoy
A1 Deborah Cromer
A1 James Emmanuel San
A1 Shi-Hsia Hwa
A1 Jennifer Giandhari
A1 Jonathan M. Blackburn
A1 Bernadett I. Gosnell
A1 Salim S. Abdool Karim
A1 Willem Hanekom
A1 NGS-SA
A1 COMMIT-KZN Team
A1 Anne von Gottberg
A1 Jinal Bhiman
A1 Richard J. Lessells
A1 Mahomed-Yunus S. Moosa
A1 Miles P. Davenport
A1 Tulio de Oliveira
A1 Penny L. Moore
A1 Alex Sigal
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267417.abstract
AB The emergence of the SARS-CoV-2 Omicron variant, first identified in South Africa, may compromise the ability of vaccine and previous infection (1) elicited immunity to protect against new infection. Here we investigated whether Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine in people who were vaccinated only or vaccinated and previously infected. We also investigated whether the virus still requires binding to the ACE2 receptor to infect cells. We isolated and sequence confirmed live Omicron virus from an infected person in South Africa. We then compared neutralization of this virus relative to an ancestral SARS-CoV-2 strain with the D614G mutation. Neutralization was by blood plasma from South African BNT162b2 vaccinated individuals. We observed that Omicron still required the ACE2 receptor to infect but had extensive escape of Pfizer elicited neutralization. However, 5 out of 6 of the previously infected, Pfizer vaccinated individuals, all of them with high neutralization of D614G virus, showed residual neutralization at levels expected to confer protection from infection and severe disease (2). While vaccine effectiveness against Omicron is still to be determined, these data support the notion that high neutralization capacity elicited by a combination of infection and vaccination, and possibly by boosting, could maintain reasonable effectiveness against Omicron. If neutralization capacity is lower or wanes with time, protection against infection is likely to be low. However, protection against severe disease, requiring lower neutralization levels and involving T cell immunity, would likely be maintained.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council awards (AS, TdO, PLM). PLM is also supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection and/or vaccinated individuals who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). Use of residual swab sample was approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M210752).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript